Published in Cancer Immunol Immunother on September 01, 2000
Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol (2003) 1.02
Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol (2006) 0.99
Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm (2009) 0.84
Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. World J Gastroenterol (2014) 0.81
Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer (2003) 0.76
Combination of three-gene immunohistochemical panel and magnetic resonance imaging-detected extramural vascular invasion to assess prognosis in non-advanced rectal cancer patients. World J Gastroenterol (2016) 0.75
Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother (1996) 1.32
Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation (2001) 0.98
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood (2001) 0.88
Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapy which should not be underestimated. Cancer Biother Radiopharm (1998) 0.87
Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother (1994) 0.87
Human leukocyte antigen-A, -B, and -Cw polymorphism in a Berber population from North Morocco using sequence-based typing. Tissue Antigens (2004) 0.86
The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother (1998) 0.85
Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother (1999) 0.85
Comparison between HLA-DR serologic typing and oligotyping in kidney transplant: a single center experience. Transplant Proc (1993) 0.83
Immunosorbent treatment in myasthenia gravis. Prog Clin Biol Res (1990) 0.80
The TH1 and TH2 cytokine network in healthy subjects: suggestions for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatments. Cancer Biother Radiopharm (2000) 0.80
Transplantation of mesencephalic cell suspension in dopamine-denervated striatum of the rat.I. Effects on spontaneous activity of striatal neurons. Exp Neurol (1996) 0.80
Correlation between genetic HLA class I and II polymorphisms and anthropological aspects in the Chaouya population from Morocco (Arabic speaking). Tissue Antigens (2010) 0.80
Blockade of N-methyl-D-aspartate receptor prevents hypoxic neuronal death and cytokine release. Neuroimmunomodulation (1998) 0.79
IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. Cancer Biother Radiopharm (1997) 0.79
Radioimmunoassay typing gives a more precise definition of the HLA association of type 1 (insulin-dependent) diabetes. Diabetologia (1986) 0.79
Flow cytometric analysis of antidonor-specific antibodies in liver transplant. Transplant Proc (1997) 0.79
Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients. Int J Immunopathol Pharmacol (2010) 0.79
HLA antigens and neuroleptic response in clinical subtypes of schizophrenia. J Psychiatr Res (1989) 0.78
Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm (1996) 0.78
HLA antigens and infantile psoriasis. Acta Derm Venereol Suppl (Stockh) (1989) 0.78
Renal allograft immune response is influenced by patient and donor cytokine genotypes. Transplant Proc (2007) 0.78
[Surgical complications following pancreaticoduodenectomy: results of a single center experience]. G Chir (2003) 0.78
Relationships between the activity of MMP1/TIMP1 enzymes and the TH1/TH2 cytokine network. Cancer Biother Radiopharm (1999) 0.77
CD1a and CD1e allele frequencies in an Italian population from the Abruzzo region. Int J Immunopathol Pharmacol (2007) 0.77
The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy. Cancer Biother Radiopharm (1997) 0.77
Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats. Drugs Exp Clin Res (1991) 0.77
Cytokine levels in amniotic fluid: a marker of preterm labor? Clin Exp Obstet Gynecol (2006) 0.77
Inhibitory effects of gangliosides and cyclosporine on lymphocyte activation: analysis of cytokine gene mRNA transcripts. Transplant Proc (1993) 0.77
Identification of the novel HLA-A*9250 allele by sequence-based typing in a Caucasian bone marrow donor from Italy. Tissue Antigens (2008) 0.76
Identification of a novel HLA-B allele, HLA-B*3580, with possible implication in transplantation and CTL response. Tissue Antigens (2007) 0.76
[Transplantation of the kidney in the rat. I. Problems of surgical technic]. Boll Soc Ital Biol Sper (1979) 0.76
Sequence-based typing characterization of the novel HLA-Cw*1609 allele in the Moroccan Chaouya group. Tissue Antigens (2007) 0.76
Genetic markers of cluster headache and the links with the lithium salts therapy. Int J Clin Pharmacol Res (1986) 0.76
HLA-B14 antigen in cluster headache. Headache (1984) 0.76
A new HLA-A allele identified in a leukemic patient attending hematopoietic cell transplantation: A*2318. Tissue Antigens (2008) 0.75
Identification of the very uncommon allele HLA-Cw*0716 in a Caucasian renal transplant recipient: extension of the exon 4 sequence. Tissue Antigens (2007) 0.75
B*3812: a new HLA-B38 variant identified by sequence-based typing. Tissue Antigens (2006) 0.75
Identification of the uncommon allele HLA-A*7403 in a Caucasian renal transplant cadaveric donor: extension of the exon 4 sequence. Tissue Antigens (2007) 0.75
A new HLA-CW*14 allele, Cw*140204, identified by allele-specific DNA amplification and sequencing. Tissue Antigens (2006) 0.75
Anti-HLA antibodies in kidney transplanted patients. Transplant Proc (2005) 0.75
Early organ toxicity following allogeneic bone marrow transplantation in congenital hemopathies. Bone Marrow Transplant (1996) 0.75
Unrelated living donor kidney transplant and developing countries. Transplant Proc (1992) 0.75
[Surgical anatomy of the rat portal system]. Boll Soc Ital Biol Sper (1978) 0.75
Microprotein kinetics in dialysis. Beta-2-microglobulin and heparin-free hemodialysis. Contrib Nephrol (1989) 0.75
Identification of a novel HLA-DRB1*11 allele: DRB1*1152. Tissue Antigens (2006) 0.75
Transplant organization in Italy. Transplant Proc (1992) 0.75
Sequence analysis of a new HLA-DR11 allele in a Caucasian Italian family: DRB1*11272. Tissue Antigens (2000) 0.75
T-lymphocyte subsets modifications in multiple sclerosis: correlation with clinical disease activity. Ital J Neurol Sci (1986) 0.75
Posttransplant donor-specific antibody characterization and kidney graft survival. Transpl Int (2000) 0.75
HLA-DR matching and graft survival in heart transplant. Transplant Proc (1990) 0.75
Waiting list for kidney transplants. Transplant Proc (2005) 0.75
Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm (1996) 0.75
Gangliosides potentiate cyclosporine A-induced suppression of allospecific immune responses. Transplant Proc (1991) 0.75
Monitoring after transplantation in liver and kidney transplant recipients with anti-donor HLA antibodies. Transplant Proc (1993) 0.75
Interleukin 1-beta modulates the effects of hypoxia in neuronal culture. J Neuroimmunol (2000) 0.75
Hepatitis C virus infection in kidney transplant recipients. Transplant Proc (1993) 0.75
Genotyping analysis of HLA class II genes in donor-recipient kidney transplant pairs. Transplant Proc (1993) 0.75
Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm (1996) 0.75
[HLA antigens and chronic alcoholic liver diseases]. Minerva Dietol Gastroenterol (1988) 0.75
Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation. Transplant Proc (1998) 0.75
Low responsiveness to Candida antigens in kidney transplant recipients. Microbiologica (1991) 0.75
Disease stage prognostic indices in the early clinical screening of colorectal cancer patients. Cancer Biother Radiopharm (1998) 0.75
Subcutaneous administration of interleukin-2 triggers Fcgamma receptor I expression on human peripheral blood neutrophils in solid and hematologic malignancies. J Immunother (2001) 0.75
Characterization of a novel HLA-Cw*02 variant, Cw*0208, in a Caucasian individual. Tissue Antigens (2005) 0.75
HLA-DR matching and anti-donor-specific antibodies in kidney transplant recipients. Transplant Proc (1992) 0.75
[Portacaval anastomosis in the rat. 1. Surgical technic]. Boll Soc Ital Biol Sper (1978) 0.75
RT-PCR analysis of immune-modulating factors in PBMCs from patients with cancer: reduced IL-2 and increased IL-2-receptor (p55) expression characterize gastroenteric neoplasms. Anticancer Res (1999) 0.75
Relevance of posttransplant HLA class I and class II antibodies on renal graft outcome. Transplant Proc (2001) 0.75
HLA class I residue mismatch and renal graft outcome. Transpl Int (2000) 0.75
Cytokine contribution to the repair processes and homeostasis recovery following anoxic insult: a possible IFN-gamma-regulating role in IL-1beta neurotoxic action in physiological or damaged CNS. Neuroimmunomodulation (1997) 0.75
Identification of the novel allele B*4427 and a confirmatory sequence (B*44022). Tissue Antigens (2002) 0.75
[Heart transplantation: the role of histocompatibility]. Minerva Chir (1992) 0.75
Developing countries as the major future source of living donor renal transplants. Transplant Proc (1992) 0.75
Transplantation of mesencephalic cell suspension in dopamine-denervated striatum of the rat. II. Effects on corticostriatal transmission. Exp Neurol (1997) 0.75
Kidney transplant monitoring by anti donor specific antibodies. Transpl Int (1992) 0.75
Treatment of thalassemia by allogeneic bone marrow transplantation. Bone Marrow Transplant (1993) 0.75
Flow cytometry crossmatching in donor/recipient selection. Transplant Proc (1991) 0.75
The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm (1997) 0.75
Flow cytometry crossmatch and kidney graft outcome. Transplant Proc (1999) 0.75
Identification of factors interacting with a subset of T8+ cells. Riv Neurol (1987) 0.75
[Metabolic changes after extended hepatic resection]. Minerva Chir (1979) 0.75
Gangliosides potentiate the immunosuppressive effects of cyclosporin A in rat skin allografts. Transpl Int (1992) 0.75
Identification of a novel HLA-A*02 allele, A*027401*. Tissue Antigens (2005) 0.75
Cell cycle control in cellular homeostasis during the immune response: interactions between TH1, TH2 cytokines, and Bcl2 and p53 molecules. Cancer Biother Radiopharm (2001) 0.75
Immunologic monitoring in kidney transplantation. Transplant Proc (1991) 0.75
Improving screening strategies for HLA-specific antibody detection in renal transplant recipients. Transplant Proc (2001) 0.75
Antidonor-HLA antibodies and soluble HLA antigens after kidney transplant. Transplant Proc (1993) 0.75